NCT04397107View on ClinicalTrials.gov

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

June 30, 2022

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

IL-2

Patients were received low dose recombinant human Interleukin-2

Trial Locations (1)

130000

Sirui Yang, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT04397107 - The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases | Biotech Hunter | Biotech Hunter